<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput xmlns:ns2="local"><serviceExecutionTime>284</serviceExecutionTime><Trial id="1"><TitleDisplay>A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK-933776) in Patients With Alzheimer's Disease</TitleDisplay><TitleOfficial>A Randomized, Single-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of GSK-933776 in Patients With Alzheimer's Disease</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">106006</Identifier><Identifier type="NCT">NCT00459550</Identifier><Identifier type="Other">2006-004014-41</Identifier><Identifier type="Other">BA1106006</Identifier></Identifiers><Indications><Indication id="14">Alzheimers disease</Indication></Indications><BiomarkerNames><BiomarkerName id="568" role="Therapeutic effect marker" type="Genomic;Proteomic">Amyloid beta A4 protein</BiomarkerName><BiomarkerName id="900" role="Therapeutic effect marker" type="Genomic;Proteomic">Microtubule associated protein tau</BiomarkerName><BiomarkerName id="5093" role="Therapeutic effect marker" type="Genomic">P protein</BiomarkerName><BiomarkerName id="10962" role="Therapeutic effect marker" type="Genomic;Proteomic">Complement factor I</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>GSK-933776A</Name><Drug id="57403">GSK-933776A</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="57403">GSK-933776A</Drug><IndicationsPioneer><Indication id="14">Alzheimers disease</Indication></IndicationsPioneer><Companies><Company><Company id="28355">GlaxoSmithKline plc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="57403" type="Drug"><TargetEntity id="451207" type="siDrug">933776</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"></TargetEntity><TargetEntity id="331.0" type="ICD9"></TargetEntity><TargetEntity id="10012271" type="MEDDRA"></TargetEntity><TargetEntity id="D000544" type="MeSH"></TargetEntity><TargetEntity id="-1268969445" type="omicsDisease"></TargetEntity><TargetEntity id="101" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="7343" type="Action"><TargetEntity id="966" type="Mechanism">beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors</TargetEntity><TargetEntity id="2200" type="Mechanism">Anti-A beta Peptide</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>7</NumberOfSites><CompaniesSponsor><Company id="28355">GlaxoSmithKline plc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="7343">Beta amyloid antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="284">Nootropic agent</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="51">Monoclonal antibody</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>50</PatientCountEnrollment><PatientCountEvaluable>50</PatientCountEvaluable><DateStart>2007-03-12T00:00:00Z</DateStart><DateEnd type="actual">2011-05-30T00:00:00Z</DateEnd><DateChangeLast>2019-05-30T07:30:42Z</DateChangeLast><DateAdded>2007-07-20T14:54:39Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>GSK Clinical Disclosure</Affiliation><Name>Cheri Hudson</Name></Contact><Contact type="Scientific contact"><Affiliation>GlaxoSmithKline</Affiliation><Name>GSK Clinical Trials</Name></Contact><Contact type="Scientific contact"><Affiliation>GlaxoSmithKline</Affiliation><Name>GSK Clinical Trials</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male or female subject with a clinical diagnosis of probable Alzheimer's disease (AD)&lt;/li&gt;&lt;li&gt;Subject has mild AD with Mini Mental State Examination (MMSE) score 18 to 26 inclusive at the screening visit&lt;/li&gt;&lt;li&gt;Age between 55 and 80 years&lt;/li&gt;&lt;li&gt;Female subjects must be post-menopausal or surgically sterile&lt;/li&gt;&lt;li&gt;Male subjects whose partner is of child-bearing potential or have been menopausal for less than two  years must use an adequate form of contraception&lt;/li&gt;&lt;li&gt;Subject has the ability to comply with procedures for cognitive and other testing and is fluent in the language used for the administration of the cognitive tests&lt;/li&gt;&lt;li&gt;Subject lives with (or has substantial periods of contact with) a permanent caregiver who is willing to attend all visits, oversee the subject's compliance with protocol-specified procedures and study medication, and report on subject's status&lt;/li&gt;&lt;li&gt;Subject has provided full written informed consent prior to the performance of any protocol-specified procedure&lt;/li&gt;&lt;li&gt;Caregiver has provided a full written informed consent on his/her own behalf prior to the performance of any protocol-specified procedure&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;History and/or evidence of any other central nervous system (CNS) disorder that could be interpreted as a cause of dementia&lt;/li&gt;&lt;li&gt;Subjects currently living in a nursing home&lt;/li&gt;&lt;li&gt;Subjects who are unable to provide informed consent due to cognitive status&lt;/li&gt;&lt;li&gt;Screening brain MRI not consistent with AD and/or has evidence of other CNS conditions listed in criterion one, and/or shows more than minimal vascular changes&lt;/li&gt;&lt;li&gt;Any contraindication to lumbar puncture&lt;/li&gt;&lt;li&gt;History of significant psychiatric illness such as schizophrenia or bipolar affective disorder or significant neurological disease other than AD&lt;/li&gt;&lt;li&gt;TIA/stroke in the last three years, type 1 or type 2 diabetes mellitus, active cardiovascular disease, or other uncontrolled risk factors for stroke&lt;/li&gt;&lt;li&gt;Current or recent drug or alcohol abuse or dependence or recent or remote history of the same if that could be a contributing factor to the dementia&lt;/li&gt;&lt;li&gt;History or evidence of any significant autoimmune disease or disorder&lt;/li&gt;&lt;li&gt;History of seizures (excluding febrile seizures in childhood), current blood clotting or bleeding disorder or conditions that predispose to these (eg, cancer), current clinically significant systemic illness or significant infection within 30 days that is likely to result in deterioration of the subject's condition or affect the subject and apos safety during the study&lt;/li&gt;&lt;li&gt;Any other significant medical illness in the past 12 months before screening that is likely to affect subject's safety in the study&lt;/li&gt;&lt;li&gt;Subjects who have discontinued cholinesterase inhibitors, memantine, cognitive enhancing agents, or drugs that potentially affect cognition in the 60 days prior to screening&lt;/li&gt;&lt;li&gt;Unless maintained on a stable dose regimen for at least 30 days prior to screening, any other medications with the potential to affect cognition&lt;/li&gt;&lt;li&gt;Use of drugs with platelet anti-aggregant or anti-coagulant properties (excluding the use of aspirin 325 mg/day or less), anticonvulsants for seizures or narcotic medication&lt;/li&gt;&lt;li&gt;History of or current chronic use of systemic steroids or other immunosuppressants&lt;/li&gt;&lt;li&gt;Prior participation in clinical investigations involving therapeutic monoclonal antibodies or proteins derived from monoclonal antibodies or any investigations of treatments or use of experimental medications for AD or any other investigational medication or device within 60 days prior to screening or within five half-lives of use of such a medication prior to screening, whichever is longer&lt;/li&gt;&lt;li&gt;Contraindications for MRI: pacemaker, aneurysm clips, artificial heart valves, other metal foreign body, claustrophobia, etc&lt;/li&gt;&lt;li&gt;Smoking &gt; 20 cigarettes or equivalent per day&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Adverse events: Changes suggesting potential adverse events detected in the physical and neurological examination, brain MRI, cognitive status, laboratory parameters, ECG and vital signsChanges suggesting potential adverse events detected in the physical and neurological examination, brain MRI, cognitive status, laboratory parameters, ECG and vital signs</Description><Timeframe>12 weeks for Part A; 34 weeks in Part B</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Plasma pharmacokinetic parameters of GSK-933776A</Description><Timeframe>12 weeks for Part A; 34 weeks in Part B</Timeframe></Measure><Measure><Description>Pharmacodynamic effects of GSK-933776A</Description><Timeframe>12 weeks for Part A; 34 weeks in Part B</Timeframe></Measure><Measure><Description>CSF detectable levels of GSK-933776</Description><Timeframe>12 weeks for Part A; 34 weeks in Part B</Timeframe></Measure><Measure><Description>Effects of GSK-933776 on plasma and CSF biomarkers</Description><Timeframe>12 weeks for Part A; 34 weeks in Part B</Timeframe></Measure><Measure><Description>Titre and neutralising activity of anti-GSK-933776 antibodies</Description><Timeframe>12 weeks for Part A; 34 weeks in Part B</Timeframe></Measure><Measure><Description>Exploratory PET scan</Description><Timeframe>12 weeks for Part A; 34 weeks in Part B</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Results were published in 2013. There were no cases of vasogenic oedema during the treatment and there were occurance of gout and  transient ischaemic reported during the treatment with &lt;ulink linkType="Drug" linkID="57403"&gt;GSK-933776A&lt;/ulink&gt;,  but these were not related to the drug treatment. There were no clinically significant changes in the electrocardiogram, vital signs or clinical laboratory and magnetic resonance imaging findings were reported during the treatment period. One subject receing placebo reported to have a novel microbleed. There was occurance of  novel anti-GSK-933776 antibodies reported in two subjects one of which was neutralising with antibody titre up to 80 and there was no increae in the titers during the treatment period. There was no statistically significant reports of the neuropsychological tests. The commonly observed adverse events at diffrent doses were  fatigue, nasopharyngitis,  nausea, vomiting,  dizziness, confusional state, diarrhea, hematoma and increase in the  blood creatine phosphokinase [&lt;ulink linkType="Reference" linkID="1511226"&gt;1511226&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this   study was to investigate the safety and tolerability of both single and multiple iv administrations of &lt;ulink linkType="Drug" linkID="57403"&gt;GSK-933776A&lt;/ulink&gt; in patients with Alzheimer's disease.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were published in 2013. In plasma: the clearance of the population and the volume of distribution of the central compartment at the doses &gt;/= 1 mg/kg was found to be 0.132 ml/h/kg and 40.7 ml/kg  respectively, whereas at  0.1 mg/kg they were found to be approximately 0.272 ml/h/kg and 72.8 ml/kg  respectively. The half-life of the terminal phase ranged from 10 to 15 days. In the part B of the study the volume of distribution at steady-state (Vdss) was found to be 103.63 ml/kg at 0.1 mg/kg , 59.96, 60.92 and 45.72 ml/kg at 1, 3 and 6 mg/kg, respectively. After the first administration of the &lt;ulink linkType="Drug" linkID="57403"&gt;GSK-933776&lt;/ulink&gt; there was a total increase in the Abeta levels and decrease in the free Abeta levels reported which was dose dependent and there was a significant change after  administration of 1, 3 and 6 mg/kg doses. The peak : trough ratios of the Abeta 1 to 42 and 1 to 34 were &amp;lt;/= 2 at doses 3 and 6 mg/kg, respectively. There was no effect of placebo reported on the Abeta levels. In cerebrospinal fluid:The subjects receiving &lt;ulink linkType="Drug" linkID="57403"&gt;GSK-933776&lt;/ulink&gt; ie, two at 1 mg/kg, five at 3 mg/kg and five at 6mg/kg reported detectable concentrations at day 78. The ratios of the mean of the CSF versus plasma concentration at day 78 were 0.217% at 6 mg/kg observed in four subjects and 0.272% at 3 mg/kg observed in five subjects. After the administration of the 6 mg/kg dose of &lt;ulink linkType="Drug" linkID="57403"&gt;GSK-933776&lt;/ulink&gt; the Abeta 1 to 38 was increased and there was also increase in the Abeta levels reported after receiving placebo. There were no changes in the APOE, tau or P-tau during the treatment with &lt;ulink linkType="Drug" linkID="57403"&gt;GSK-933776&lt;/ulink&gt; or placebo. There were six subjects from the single dose who re-entered the repeated dose. The APOE epsilon4 carrier frequency was similar in all the subjetcs and there were nine subjects with two
copies of the APOE epsilon4 allele [&lt;ulink linkType="Reference" linkID="1511226"&gt;1511226&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In May 2016, results were presented. GSK-933776 blocked beta amyloiod mimics (BAMs) and inhibited complement factor-1 (CF-1) bioactivity dose dependently with an EC50 of 20 microg/ml. In plasma samples from Alzheimer's patients, GSK-933776 treatment resulted in an increase of 10 and 27% in CF-1 bioactivity. Estimated time to steady state was 6 h, however, after three doses of GSK-933776, the levels of total BAM were not at steady state [&lt;ulink linkType="Reference" linkID="1752067"&gt;1752067&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Part A would be a single-blind, single-dose, placebo-controlled, dose-escalation study in up to five consecutive cohorts of Alzheimers Disease subjects. Each subject  would receive a single infusion of &lt;ulink linkType="Drug" linkID="57403"&gt;GSK-933776&lt;/ulink&gt; or placebo. The dose for the first cohort would be 0.001 mg/kg. The proposed nominal doses for subsequent cohorts are 0.01, 0.1, 0.5 and 3 mg/kg, but these might be altered based on the outcome of the safety, tolerability, pharmacodynamic and pharmacokinetic data of the preceding group(s). The maximum possible dose would be 20 mg/kg, although the planned top dose is 18 mg/kg.&lt;/para&gt;&lt;para&gt;Part B would be a single-blind, repeat-dose, placebo-controlled, dose-escalation design. It was proposed that there would be initially three cohorts of AD subjects. However up to five cohorts might be recruited if required in order to characterise &lt;ulink linkType="Drug" linkID="57403"&gt;GSK-933776&lt;/ulink&gt; fully. Each cohort would consist of eight subjects (six active, two placebo) who would each receive a maximum of three infusions of &lt;ulink linkType="Drug" linkID="57403"&gt;GSK-933776&lt;/ulink&gt; or placebo. &lt;/para&gt;&lt;para&gt;Dosing in Part B would  proceed in parallel with Part A following satisfactory review of minimum data sets as below:&lt;br/&gt;First cohort in Part B: at least 3 weeks' data from the Part A dose that was the same dose level as that planned for Part B. &lt;br/&gt;Second cohort in Part B: at least 3 weeks pharmacokinetic (PK) data and 8 weeks safety data following the first dose from all the subjects on active treatment in the preceding Part B cohort plus a satisfactory outcome of the PIB. &lt;br/&gt;Subsequent cohorts in Part B: at least 3 weeks PK data and 8 weeks safety data follow.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Subjects would be randomized into two parts of the study:&lt;br/&gt;Part A: subjects of the three single-dose (SD) cohorts were dosed with &lt;ulink linkType="Drug" linkID="57403"&gt;GSK-933776&lt;/ulink&gt; (0.001, 0.01 and 0.1 mg/kg), the dosing in new cohort began only q3w. The duration of each subject in this part of the study was for 4 to 7 months including from screening follow-up period.&lt;br/&gt;Part B: subjects of the four cohorts were dosed with &lt;ulink linkType="Drug" linkID="57403"&gt;GSK-933776&lt;/ulink&gt; (0.1, 1, 3 and 6 mg/kg). The duration of each subject in this part of the study was for 9 to 12 months including from screening follow-up period [&lt;ulink linkType="Reference" linkID="1511226"&gt;1511226&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1752067"&gt;1752067&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>GSK-933776A</Name><Drug id="57403">GSK-933776A</Drug><Dose unit="milligram/kg dose">0.001</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsTotal>33</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>GSK-933776A</Name><Drug id="57403">GSK-933776A</Drug><Dose unit="milligram/kg dose">0.01</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="2274">Rhinopharyngitis</Indication><CountPatientsTotal>33</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>GSK-933776A</Name><Drug id="57403">GSK-933776A</Drug><Dose unit="milligram/kg dose">0.1</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="110">Emesis</Indication><CountPatientsTotal>17</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsTotal>17</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="2274">Rhinopharyngitis</Indication><CountPatientsTotal>33</CountPatientsTotal><CountPatientsAffected>2</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="3454">Dizziness</Indication><CountPatientsTotal>17</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication><CountPatientsTotal>33</CountPatientsTotal><CountPatientsAffected>2</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>GSK-933776A</Name><Drug id="57403">GSK-933776A</Drug><Dose unit="milligram/kg dose">1.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsTotal>33</CountPatientsTotal><CountPatientsAffected>2</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="110">Emesis</Indication><CountPatientsTotal>17</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="1956">Confusion</Indication><CountPatientsTotal>17</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsTotal>17</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication><CountPatientsTotal>17</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>GSK-933776A</Name><Drug id="57403">GSK-933776A</Drug><Dose unit="milligram/kg dose">3.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="2274">Rhinopharyngitis</Indication><CountPatientsTotal>17</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication><CountPatientsTotal>33</CountPatientsTotal><CountPatientsAffected>2</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>GSK-933776A</Name><Drug id="57403">GSK-933776A</Drug><Dose unit="milligram/kg dose">6.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="110">Emesis</Indication><CountPatientsTotal>33</CountPatientsTotal><CountPatientsAffected>2</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsTotal>17</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="3454">Dizziness</Indication><CountPatientsTotal>33</CountPatientsTotal><CountPatientsAffected>2</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication><CountPatientsTotal>17</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="1">GSK-933776A</Intervention><Treatments><Treatment><Dose>0.001 milligram/kg</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>0.01 milligram/kg</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>0.1 milligram/kg</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>1 milligram/kg</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>3 milligram/kg</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>6 milligram/kg</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Australia"><Sites><Site><Name>GSK Investigational Site</Name><Address1>Fremantle</Address1><Address2>Western Australia</Address2><Address3>6160</Address3><CountrySubDivision>Western Australia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Heidelberg Heights</Address1><Address2>Victoria</Address2><Address3>3084</Address3><CountrySubDivision>Victoria</CountrySubDivision><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Herston</Address1><Address2>Queensland</Address2><Address3>4029</Address3><CountrySubDivision>Queensland</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Norway"><Sites><Site><Name>GSK Investigational Site</Name><Address1>Lørenskog</Address1><Address3>1478</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Sweden"><Sites><Site><Name>GSK Investigational Site</Name><Address1>Malmö</Address1><Address3>SE-205 02</Address3><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Mölndal</Address1><Address3>SE-431 41</Address3><Contacts></Contacts></Site><Site><Name>GSK Investigational Site</Name><Address1>Stockholm</Address1><Address3>se-141 86</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Alzheimers disease</Disease><PatientSegments><PatientSegment><PatientSegment id="159">Subjects with Probable Diagnosis of Alzheimer's Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="161">Subjects with Mild Alzheimer's Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="162">Subjects with Moderate Alzheimer's Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00459550</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2006-004014-41</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Alzheimers disease" id="2236"><Endpoint>Assessment of MRI Imaging Findings</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Alzheimers disease" id="2270"><Endpoint>Assessment of Vital Signs</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Alzheimers disease" id="2286"><Endpoint>Assessment of Adverse Events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Alzheimers disease" id="2289"><Endpoint>Cognitive, Global and Functional Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Alzheimers disease" id="10720"><Endpoint>Assessment of Cardiac Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Alzheimers disease" id="2207"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="Alzheimers disease" id="2208">Analysis of CSF phospho-tau</SubEndpoint><SubEndpoint disease="Alzheimers disease" id="2209">Analysis of CSF tau</SubEndpoint><SubEndpoint disease="Alzheimers disease" id="2210">Analysis of plasma amyloid beta peptide</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Alzheimers disease" id="2242"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Alzheimers disease" id="6688">Antibody titers</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Alzheimers disease" id="2402"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Alzheimers disease" id="3800"><Criterion>Subjects with Mild Alzheimer's Disease</Criterion></Inclusion><Inclusion disease="Alzheimers disease" id="3801"><Criterion>Subjects with Moderate Alzheimer's Disease</Criterion></Inclusion><Inclusion disease="Alzheimers disease" id="3811"><Criterion>Subjects with Probable Alzheimer's Disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Alzheimers disease" id="1421"><Criterion>Subjects with other causes of dementia</Criterion></Exclusion><Exclusion disease="Alzheimers disease" id="1433"><Criterion>Abnormal MRI Findings, Other Than Suggestive of Alzheimer's Disease</Criterion></Exclusion><Exclusion disease="Alzheimers disease" id="1441"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1444">Subjects co-morbid with epilepsy/seizures</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="1457"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1467">Subjects co-morbid with schizophrenia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="1468"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Alzheimers disease" id="1483"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1458">Subjects co-morbid with bipolar disorder</SubCriterion><SubCriterion disease="Alzheimers disease" id="1476">Subjects with autoimmune diseases/disorders</SubCriterion><SubCriterion disease="Alzheimers disease" id="1490">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="1485"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Alzheimers disease" id="1504"><Criterion>Subjects with History of Alzheimer's Disease Therapy</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1511">Subjects with no history of stable doses of Alzheimer's disease therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="1512"><Criterion>Subjects Who Have Discontinued Drugs That Affect Cognition</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1513">Subjects who have discontinued acetyl cholinesterase inhibitors (AChEIs)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="1516"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1519">Subjects with history/scheduled to receive anticoagulants for other indication</SubCriterion><SubCriterion disease="Alzheimers disease" id="1524">Subjects with history of anticonvulsants</SubCriterion><SubCriterion disease="Alzheimers disease" id="1531">Subjects with history of/scheduled to receive immunosuppressants for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="1948"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Alzheimers disease" id="1952"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Alzheimers disease" id="24997"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1440">Subjects with Hypersensitivity/Contraindication to MRI</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alzheimers disease" id="27026"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Alzheimers disease" id="1442">Subjects co-morbid with stroke/transient ischemic attack</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2011-05-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2007-04-11T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2007-07-20T14:54:39Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2013-12-26T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="10000"><TitleDisplay>A Phase IIa Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study Of INS-37217 Intranasal In Patients With Upper Respiratory Infection (Common Cold)</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="516">Upper respiratory tract infection</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>denufosol tetrasodium (intranasal, upper respiratory disorder), Inspire</Name><Drug id="52898">denufosol tetrasodium (intranasal, upper respiratory disorder), Inspire</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="52898">denufosol tetrasodium (intranasal, upper respiratory disorder), Inspire</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="22360">Inspire Pharmaceuticals Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="22360" type="Company"><TargetEntity id="4295900448" type="organizationId">Inspire Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="516" type="ciIndication"><TargetEntity id="10046306" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="4882" type="Action"><TargetEntity id="939" type="Mechanism">P2Y2 Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2a Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="22360">Inspire Pharmaceuticals Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="4882">P2Y2 purinoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology id="619">Nasal formulation local</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>90</PatientCountEnrollment><PatientCountEvaluable>101</PatientCountEvaluable><DateStart>2002-05-08T00:00:00Z</DateStart><DateChangeLast>2012-02-21T09:03:16Z</DateChangeLast><Contacts><Contact type="Scientific contact"><Affiliation>University of Virginia</Affiliation><Name>Birgit Winther</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with upper respiratory infection&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Safety</Description></Measure><Measure><Description>Improvement in post-nasal drip and malaise</Description></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was  phase II multi-center, double-blind, placebo-controlled, dose-ranging study of &lt;ulink linkType="Drug" linkID="52898"&gt;INS-37217&lt;/ulink&gt; intranasal in patients with upper respiratory infection (common cold) [&lt;ulink linkType="Reference" linkID="469286"&gt;469286&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="450637"&gt;450637&lt;/ulink&gt;].  &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results have shown that &lt;ulink linkType="Drug" linkID="52898"&gt;INS-37217&lt;/ulink&gt; demonstrated significant improvement in post-nasal drip and malaise at multiple doses and on multiple days over the 14-day study period when compared to placebo. &lt;ulink linkType="Drug" linkID="52898"&gt;INS-37217&lt;/ulink&gt; intranasal was safe and well tolerated, with no  serious drug-related adverse events observed; the drug  demonstrated activity at multiple doses [&lt;ulink linkType="Reference" linkID="469286"&gt;469286&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients were dosed for 6 days and symptom scores were recorded for a total of 14 days [&lt;ulink linkType="Reference" linkID="469286"&gt;469286&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were dosed for 6 days and symptom scores were recorded for a total of 14 days [&lt;ulink linkType="Reference" linkID="469286"&gt;469286&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="10747">denufosol tetrasodium (intranasal, upper respiratory disorder), Inspire</Intervention><Treatments><Treatment><Dose>10 mg/ml</Dose><Route>Transmucosal</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType></Trial><Trial id="100000"><TitleDisplay>Stereotactic Body Radiation Therapy in Treating Patients With Low and Low-Intermediate-Risk Prostate Cancer</TitleDisplay><TitleOfficial>Study of Four-Fraction Split-Course Stereotactic Ablative Radiation Therapy of the Treatment of Patients With Low and Low-Intermediate Risk Adenocarcinoma of the Prostate</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">MCC-14712</Identifier><Identifier type="NCT">NCT01737151</Identifier><Identifier type="Secondary Organisational">NCI-2012-02545</Identifier></Identifiers><Indications><Indication id="276">Prostate tumor</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>stereotactic body radiation therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20696" type="Company"><TargetEntity id="5000493178" type="organizationId">Virginia Commonwealth University Foundation</TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"></TargetEntity><TargetEntity id="10060862" type="MEDDRA"></TargetEntity><TargetEntity id="D011471" type="MeSH"></TargetEntity><TargetEntity id="-405461207" type="omicsDisease"></TargetEntity><TargetEntity id="5083" type="siCondition"></TargetEntity><TargetEntity id="637" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="20696">Virginia Commonwealth University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>19</PatientCountEnrollment><DateStart>2013-03-08T00:00:00Z</DateStart><DateEnd type="estimated">2019-05-31T00:00:00Z</DateEnd><DateChangeLast>2019-04-02T12:24:29Z</DateChangeLast><DateAdded>2012-11-30T09:52:48Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Massey Cancer Center</Affiliation><Name>Timothy J Harris, M.D.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients must have low or low-intermediate risk adenocarcinoma of the prostate as
             defined by:&lt;ul&gt;&lt;li&gt;Low-risk diseas- histopathology score (Gleason sum)&amp;lt;/= 6, and T-stage (per current American Joint
                  Committee on Cancer [AJCC] staging criteria): T1c to T2a, and prostate-specific
                  antigen (PSA) &amp;lt; 10&lt;/li&gt;&lt;li&gt;Intermediate-risk disease as either:&lt;ul&gt;&lt;li&gt;Histopathology score (Gleason sum)&amp;lt;/= 6, and T-stage (per current American Joint
                  Committee on Cancer [AJCC] staging criteria): T1c to T2a, and prostate-specific
                  antigen (PSA) &gt;  10 or &amp;lt; 20&lt;/li&gt;&lt;li&gt;Histopathology score (Gleason sum) 7 with&amp;lt;/=  50% of any cores positive, T-stage (per current AJCC staging criteria): T1c to T2a, and PSA &amp;lt; 10&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Charlson index of comorbidity score&amp;lt;/= 4
&lt;/li&gt;&lt;li&gt;Ability to understand and the willingness to sign a written informed consent document&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with history of inflammatory bowel disease, or who require steroid or
             cytotoxic therapy for collagen vascular disease&lt;/li&gt;&lt;li&gt;Patients with a history of cancer other than skin cancer within five years of the
             initiation of protocol treatment&lt;/li&gt;&lt;li&gt;Patients with a history of pelvic irradiation for any reason&lt;/li&gt;&lt;li&gt;Life expectancy&amp;lt; 10 years &lt;/li&gt;&lt;li&gt;Prior treatment with an anti-androgen, luteinizing
             hormone-releasing hormone (LHRH) agonist, or a combination of the two&lt;/li&gt;&lt;li&gt;Prior radiation therapy, brachytherapy, or cryotherapy&lt;/li&gt;&lt;li&gt;Prior surgical procedure involving peri-rectal and peri-prostatic area&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Late toxicity &gt;/= grade 2 as defined by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteria: will be tested using a continuity corrected chi-square test</Description><Timeframe>Two years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Biochemical failure as defined by the phoenix definition</Description><Timeframe>Up to five years</Timeframe></Measure><Measure><Description>Protocol completion rate: the portion of patients completing the planned protocol with no unacceptable protocol violations is anticipated to be greater than 90%. A completion rate of 70% is deemed unacceptably low</Description><Timeframe>Up to five years</Timeframe></Measure><Measure><Description>Patient-reported outcomes: International Index of Erectile Function (IIEF) and Expanded Prostate Cancer Index Composite urinary Assessment (EPIC) urinary and bowel assessments will be used to collect patient-reported outcomes. IIEF is a widely used instrument for the evaluation of male sexual function. It is has been recommended as tool for clinical trials of erectile dysfunction and for diagnostic evaluation of erectile dysfunction severity. 15 questions 1=very low (worst) to 5=very high (best). The EPIC urinary and bowel assessments are comprehensive instruments designed to evaluate urinary and bowel symptoms, thereby providing a unique tool for assessment of quality of life issues important in prostate cancer management. 9 questions 0=no problem to 5=big problem</Description><Timeframe>Up to five years</Timeframe></Measure><Measure><Description>Acute toxicity greater than or equal to grade 2 as defined by the CTCAE version 4 criteria</Description><Timeframe>Up to 90 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized clinical trial is to study stereotactic body radiation therapy (SBRT) in treating
      patients with low- and low-intermediate-risk prostate cancer. The study hypothesis is  that stereotactic body radiation
      therapy may be able to send X-rays directly to the tumor and cause less damage to normal
      tissue.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Primary objectives:&lt;br/&gt;To evaluate, in terms of late toxicity, the safety of stereotactic radiation therapy using the proposed fractionation schedule.&lt;/para&gt;&lt;para&gt;Secondary objectives:&lt;br/&gt;To evaluate, in terms of acute toxicity, the safety of stereotactic radiation therapy using the proposed fractionation schedule.&lt;br/&gt;To determine stereotactic treatment efficacy through biochemical failure (Phoenix criteria).&lt;br/&gt;To determine the protocol completion rate.&lt;br/&gt;To describe patient-reported outcomes using International Index of Erectile Function (IIEF) and EPIC Urinary and Bowel Assessment questionnaires.&lt;/para&gt;&lt;para&gt;Outline: &lt;br/&gt;Patients will be  randomized to one of two treatment arms.&lt;br/&gt;Arm A (standard SBRT): patients will undergo standard daily fractions of SBRT over 7 to 8.5 weeks.&lt;br/&gt;Arm B (four fraction split-course SBRT): patients will undergo two fractions of SBRT durings weeks 1 and 4.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Hunter Holmes McGuire VA Medical Center</Name><Address1>Richmond</Address1><Address2>Virginia</Address2><Address3>23249</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Virginia Medical Center</Name><Address1>Charlottesville</Address1><Address2>Virginia</Address2><Address3>22908</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Virginia Commonwealth University/Massey Cancer Center</Name><Address1>Richmond</Address1><Address2>Virginia</Address2><Address3>23298</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Prostate tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="12018">Subjects with adenocarcinoma of prostate</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="17870">Subjects at risk of disease recurrence</PatientSegment><SubSegments><SubSegment id="3567">Subjects with Intermediate Risk of Recurrence</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01737151</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Prostate tumor" id="7189"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7190">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Prostate tumor" id="7103"><Endpoint>Assessment of Clinical Response</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7104">Assessment of biochemical failure</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7189"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7194">Assessment of acute toxicity</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Prostate tumor" id="3697"><Criterion>Subjects with Specified Gleason Grade</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3699">Subjects with grade 5-7 (intermediate grade)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3702"><Criterion>Subjects with Intermediate Risk Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3714"><Criterion>Subjects with Histologically/Cytologically Confirmed Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3715">Subjects with adenocarcinoma of prostate</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3716"><Criterion>Subjects with Prostate Specific Laboratory Values</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3719">Subjects with specified PSA levels</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Prostate tumor" id="4845"><Criterion>Subjects with Advanced/Metastatic Prostate Cancer</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4909"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4918"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4899">Subjects with Auto-immune/Inflammatory diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="4936"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4965"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4968">Subjects on prior/concurrent radiotherapy</SubCriterion><SubCriterion disease="Prostate tumor" id="4969">Subjects with prior/concurrent surgery</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-11-09T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2015-08-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>29.77 Months</EnrollmentPeriod><EnrollmentRate>0.64 Patients/Month</EnrollmentRate><DateFirstReceived>2012-11-26T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-11-30T09:52:48Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2015-10-26T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-04-04T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change></ChangeHistory></Trial><Trial id="100001"><TitleDisplay>Prediction of Response to Erythropoietin Treatment in Cancer Related Anemia Patients Receiving Chemotherapy</TitleDisplay><TitleOfficial>Prediction of Response to Erythropoietin Treatment in Cancer Related Anemia Patients Receiving Chemotherapy</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">CR016558</Identifier><Identifier type="NCT">NCT01736215</Identifier><Identifier type="Secondary Organisational">EPOCAN4028</Identifier></Identifiers><Indications><Indication id="17">Anemia</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="1051" role="Therapeutic effect marker" type="Genomic;Proteomic">Ferritin</BiomarkerName><BiomarkerName id="1221" role="Therapeutic effect marker" type="Physiological">Hematocrit</BiomarkerName><BiomarkerName id="1236" role="Therapeutic effect marker" type="Biochemical">Hemoglobin</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>erythropoietin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="17392" type="Company"><TargetEntity id="4296968679" type="organizationId">Janssen-Cilag Ltd</TargetEntity></SourceEntity><SourceEntity id="28877" type="Company"><TargetEntity id="5001218222" type="organizationId">Mahidol University</TargetEntity></SourceEntity><SourceEntity id="17" type="ciIndication"><TargetEntity id="10002034" type="MEDDRA"></TargetEntity><TargetEntity id="D000740" type="MeSH"></TargetEntity><TargetEntity id="-201701473" type="omicsDisease"></TargetEntity><TargetEntity id="988" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="17392">Janssen-Cilag Ltd</Company></CompaniesSponsor><CompaniesCollaborator><Company id="28877">Mahidol University</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>33</PatientCountEnrollment><DateStart>2010-11-30T00:00:00Z</DateStart><DateEnd type="actual">2012-02-29T00:00:00Z</DateEnd><DateChangeLast>2019-01-26T04:04:06Z</DateChangeLast><DateAdded>2012-12-03T12:18:21Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Janssen-Cilag Ltd.,Thailand</Affiliation><Name>Janssen-Cilag Ltd.,Thailand Clinical Trial</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Non-hematological malignancy&lt;/li&gt;&lt;li&gt;Life expectancy at least 6 months based on the investigators clinical judgement&lt;/li&gt;&lt;li&gt;Receiving chemotherapy&lt;/li&gt;&lt;li&gt;Have indication and plan to receiving erythropoietin (dosage and regimen should
             comply with Thai FDA approval package insert)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with anemia due to other factors (ie, Iron, B12 or folate deficiencies,
             hemolysis, gastrointestinal bleeding, or any active bleeding)&lt;/li&gt;&lt;li&gt;Previous history of erythropoietin treatment&lt;/li&gt;&lt;li&gt;Patients who have received blood transfusion within 1 month before starting
             erythropoietin therapy&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Percentage of patients with response to erythropoietin treatment: responders of erythropoietin treatment were defined as patients who achieved at least 1 g/dl) rise from baseline in hemoglobin level during within 4 to 8 weeks or patients who achieved 12 g/dl hemoglobin level at anytime during the study evaluation period (about 8 weeks of follow-up, hemoglobin level reached to 12 g/dl or patients who received blood transfusion at any time of study period) based on National Comprehensive Cancer Institute (NCCN) V3.2009 practice guideline criteria</Description><Timeframe>8 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Reticulocyte count: reticulocytes are immature red blood cells</Description><Timeframe>Baseline, weeks 1, 2, 4 and 8</Timeframe></Measure><Measure><Description>Transferring iron binding capacity(TIBC): TIBC is a medical laboratory test that measures the blood's capacity to bind iron with transferrin</Description><Timeframe>Baseline, weeks 1 and 2</Timeframe></Measure><Measure><Description>Serum hemoglobin level: hemoglobin is defined as a substance that carries oxygen and gives blood its red color</Description><Timeframe>Baseline, weeks 1, 2, 4 and 8</Timeframe></Measure><Measure><Description>Serum ferritin level: serum ferritin is the amount of ferritin in a patient blood. Ferritin is a protein that stores iron and allows the body to use iron</Description><Timeframe>Baseline, weeks 1 and 2</Timeframe></Measure><Measure><Description>Serum iron level: serum iron is a test that measures the amount of iron in the blood which is bound to transferrin</Description><Timeframe>Baseline, weeks 1 and 2</Timeframe></Measure><Measure><Description>Number of patients with C-reactive protein (CRP) level &lt;/= 10.3 or &gt; 10.4: CRP is a acute serum protein released from liver. it is associated with low hemoglobin or erythropoeitin resistance. number of patients with CRP level &lt;/= 10.3 or &gt; 10.4 were observed</Description><Timeframe>Baseline</Timeframe></Measure><Measure><Description>Number of patients with serum erythropoietin (EPO) level (EPO &lt;/= 45.2 or EPO &gt; 45.3): EPO is a hormone secreted by kidney that helps in formation of red blood cells in bone marrow. Number of patients with EPO level &lt;/= 45.2 or &gt; 45.3 were observed</Description><Timeframe>Baseline</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate the predictors of response to erythropoietin
      treatment in cancer related anemia patients receiving chemotherapy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This was a single-center, prospective, observational study to identify
      the predictive factors that would effectively predict the response to erythropoietin
      treatment in anemic cancer patients who  received chemotherapy. Approximately 110
      patients would be enrolled into this study and the entire study duration would be
      approximately one year. At baseline, weeks 1, 2, 4, 8, the data from patients receiving erythropoietin treatment for the
      following laboratory parameters would be collected: hemoglobin; red blood cells count;
      hematocrit; reticulocyte count, white blood cells and platelet count; serum iron, ferritin,
      and transferring iron binding capacity; serum erythropoietin level; and C-reactive protein
      level.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;This study was terminated because of slow enrollment.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Thailand"><Sites><Site><Address1>Bangkok</Address1><Contacts></Contacts></Site><Site><Address1>Chiang Mai</Address1><Contacts></Contacts></Site><Site><Address1>Khon Kaen</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cancer supportive care</Disease><PatientSegments><PatientSegment><PatientSegment id="8982">Cancer-related Anemia</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8998">Other Chemotherapy Induced Adverse Events</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9008">General cancers</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Anemia</Disease><PatientSegments><PatientSegment><PatientSegment id="19884">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="7512">Subjects with Cancer/Cancer Chemotherapy Induced Anemia</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01736215</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Anemia" id="17219"><Endpoint>Hematological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17220">Assessment of hemoglobin status</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Cancer supportive care" id="19411"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Cancer supportive care" id="19412">Assessment of Other Treatment or Procedure Related Outcomes</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Anemia" id="17205"><Endpoint>Assessment of iron status</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17206">Assessment of serum ferritin</SubEndpoint><SubEndpoint disease="Anemia" id="17208">Assessment of total iron binding capacity</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="17219"><Endpoint>Hematological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17220">Assessment of hemoglobin status</SubEndpoint><SubEndpoint disease="Anemia" id="17228">Assessment of hematocrit</SubEndpoint><SubEndpoint disease="Anemia" id="17229">Assessment of reticulocyte count</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="17273"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17285">Assessment of Inflammatory/Immunological Markers</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="19329"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Cancer supportive care" id="19333">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="19407"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="19411"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Cancer supportive care" id="19412">Assessment of Other Treatment or Procedure Related Outcomes</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="45618"><Endpoint>Assessment of Hormone Levels</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17230">Assessment of erythropoietin level</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Cancer supportive care" id="13327"><Criterion>Other Chemotherapy Induced Adverse Events</Criterion></Inclusion><Inclusion disease="Cancer supportive care" id="13338"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13344">Subjects with life expectancy of six months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="13354"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13355">Subjects with history of anti-cancer chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="13369"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Anemia" id="14364"><Criterion>Subjects with Cancer/Cancer Chemotherapy Induced Anemia</Criterion></Inclusion><Inclusion disease="Anemia" id="14406"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14414">Subjects co-morbid with premalignant/malignant condition</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anemia" id="14417"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion></Inclusion><Inclusion disease="Anemia" id="14443"><Criterion>Subjects scheduled to receive disease specific therapy</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14444">Subjects scheduled to receive of rHuEPO therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anemia" id="14451"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion><Inclusion disease="Cancer supportive care" id="33243"><Criterion>Subjects with disease complications</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13311">Subjects with cancer related anemia</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Cancer supportive care" id="10908"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="10915">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="11787"><Criterion>Subjects with Iron Deficiency Anemia</Criterion></Exclusion><Exclusion disease="Anemia" id="11798"><Criterion>Subjects with Megaloblastic Anemia</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11799">Subjects with folic acid deficiency</SubCriterion><SubCriterion disease="Anemia" id="11800">Subjects with vitamin B12 deficiency</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="11846"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Anemia" id="11855"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11857">Subjects with history of rHuEPO therapy</SubCriterion><SubCriterion disease="Anemia" id="11864">Subjects with history of blood donation/transfusions</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="25384"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11793">Subjects with Hemolytic Anemia</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2012-02-29T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2012-11-26T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-12-03T12:18:21Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="100002"><TitleDisplay>Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability</TitleDisplay><TitleOfficial>Alcohol Research Center Grant Component 1: Naltrexone Effects on Alcohol Reactivity and Consumption, Evaluating the Genetic Variability of Naltrexone Response</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">P50AA010761</Identifier><Identifier type="NCT">NCT00366626</Identifier></Identifiers><Indications><Indication id="11">Alcoholism</Indication></Indications><BiomarkerNames><BiomarkerName id="2428" role="Disease marker" type="Genomic;Proteomic">Sodium-dependent dopamine transporter</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>naltrexone</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20675" type="Company"><TargetEntity id="4296717404" type="organizationId">Medical University of South Carolina</TargetEntity></SourceEntity><SourceEntity id="11" type="ciIndication"><TargetEntity id="F10.2" type="ICD10"></TargetEntity><TargetEntity id="10001639" type="MEDDRA"></TargetEntity><TargetEntity id="D000437" type="MeSH"></TargetEntity><TargetEntity id="-1679518733" type="omicsDisease"></TargetEntity><TargetEntity id="1119" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20675">Medical University of South Carolina</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>83</PatientCountEnrollment><PatientCountEvaluable>83</PatientCountEvaluable><DateStart>2006-04-30T00:00:00Z</DateStart><DateEnd type="actual">2010-01-31T00:00:00Z</DateEnd><DateChangeLast>2019-04-18T07:09:51Z</DateChangeLast><DateAdded>2012-12-03T06:40:02Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Medical University of South Carolina</Affiliation><Name>Raymond F Anton, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age 21 to 65 years&lt;/li&gt;&lt;li&gt;Meets the DSM IV criterion for current alcohol dependence including
'loss of control over drinking' (criterion 4) but does not necessarily have signs of
             physiological dependence as expressed in criterion for tolerance development (criterion
             1) and withdrawal symptoms or use to avoid withdrawal symptoms (criterion 2)&lt;/li&gt;&lt;li&gt;Drinks hard liquor/spirits and does not have aversion to this form of alcohol&lt;/li&gt;&lt;li&gt;Drinks alone (not in the presence of others) some of the time (to maximize the
             potential of drinking in the bar lab where a subject will not be in the company of
             others)&lt;/li&gt;&lt;li&gt;Currently is not engaged in, and does not want treatment for, alcohol related
             problems&lt;/li&gt;&lt;li&gt;Able to read and understand questionnaires and informed consent&lt;/li&gt;&lt;li&gt;Lives within
             50 miles of the study site&lt;/li&gt;&lt;li&gt;Able to maintain abstinence for 2 days (without the
             aid of detox medications) as determined by self-report and breathalyzer measurements&lt;/li&gt;&lt;li&gt;Inclusion for fMRI imaging sub-study (see methodology section for rationale)&lt;ul&gt;&lt;li&gt;Does not have metal objects in the head/neck&lt;/li&gt;&lt;li&gt;Does not have a history of claustrophobia leading to significant clinical anxiety
             symptoms&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Currently meets DSM-IV criteria for any other psychoactive substance dependence
             disorder&lt;/li&gt;&lt;li&gt;History of opiate abuse or a positive urine drug screen for opiates&lt;/li&gt;&lt;li&gt;Any
             psychoactive substance use (except marijuana and nicotine) within the last 30 days as
             evidenced by self-report and urine drug screen. For marijuana - no use within the
             last 7 days&lt;/li&gt;&lt;li&gt;Meets DSM-IV criteria for current axis I disorders of major depression, panic
             disorder, obsessive-compulsive disorder, post-traumatic stress disorder, bipolar
             affective disorder, schizophrenia, dissociative disorders and eating disorders, any
             other psychotic disorder or an organic mental disorder&lt;/li&gt;&lt;li&gt;Has current suicidal ideation or homicidal ideation&lt;/li&gt;&lt;li&gt;Need for maintenance or
             acute treatment with any psychoactive medication including anti-seizure medications&lt;/li&gt;&lt;li&gt;Current use of disulfiram, naltrexone, or acamprosate&lt;/li&gt;&lt;li&gt;Clinically significant
             medical problems such as, cardiovascular, renal, gastrointestinal, or endocrine
             problems that would impair participation or limit medication ingestion&lt;/li&gt;&lt;li&gt;Past history of alcohol related medical illness such as gastrointestinal bleeding,
             pancreatitis, peptic ulcer, hepatic cirrhosis or alcoholic hepatitis&lt;/li&gt;&lt;li&gt;Hepatocellular disease indicated by elevations of SGPT (ALT) or SGOT (AST)
             &gt; 3 times normal at screening&lt;/li&gt;&lt;li&gt;Females of child-bearing potential who are pregnant (by urine HCG), nursing, or
             who are not using a reliable form of birth control&lt;/li&gt;&lt;li&gt;Has current charges pending for a violent crime (not including DUI related
             offenses)&lt;/li&gt;&lt;li&gt;Does not have a stable living situation&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Natural alcohol consumption period; total number of drinks consumed during the 5 day Natural (Usual Environment) drinking observation period</Description><Timeframe>Treatment days 1 to 5</Timeframe></Measure><Measure><Description>Limited access alcohol consumption paradigm; total number of drinks consumed. Subjects were allowed to drink up to 8 alcohol drinks during 2 hours observation period being in bar/laboratory settings vs to get $2 per each not consumed drink</Description><Timeframe>On day 7 of treatment during limited access alcohol consuption in the bar/laboratory</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to determine whether naltrexone was more effective in the reduction of
      alcohol craving and drinking compared to placebo in individuals with particular genetic
      predisposition.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were published in November 2012. Drinking variables was not significantly affected by naltrexone or opioid receptor (OPRM1) genotype, or any medication by OPRM1 interaction. However, in individuals who had at least one dopamine transporter (DAT) 9 variable number of tandem repeat (VNTR), and who were also OPRM1 asn40 homozygotes, naltrexone reduced drinks per day consumed under natural conditions (p = 0.006), but not in the bar-lab. OPRM1 asn40 homozygotes (p = 0.028) and DAT 9 VNTR carriers (p = 0.032) had more stimulation to alcohol after the priming drink [&lt;ulink linkType="Reference" linkID="1345696"&gt;1345696&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;About 300 non-treatment seeking alcoholic subjects would be recruited and assessed, subtyped for mu-opiate receptor and catechol-O-methyltransferase (COMT) allelic variants and 88 subjects (44 with the more common AA gene and 44 with either an AG or GG gene) would be randomly assigned to take either naltrexone (50 mg/day) or a matching placebo for 7 days. Since the val and met alleles of the catechol-O-methyltransferase (COMT) gene were each present in about 50% of the subjects they would  be equally distributed by urn randomization to all opiate allele and treatment groups. After 5 days of natural drinking and one day of abstinence, subjects would undergo an alcohol cue-induced brain activity scan using well-established fMRI techniques on day 6 of study drug. The following day all subjects would receive a standard dose (gender and weight corrected) of alcohol and be evaluated for alcohol reactivity (stimulation, sedation, intoxication, craving) over 40 minutes. They then would be allowed to consume up to eight mini-drinks over a 2-h period. Afterwards all subjects would receive educational/motivational counseling regarding their alcohol use and its effects. Referral for treatment would be offered.&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Asp40 carriers (n = 43) and matched asn40 homozygotes (n = 40) were randomized to receive either naltrexone or placebo for 7 days before receiving a priming drink and limited-access alcohol consumption in a bar-lab setting  [&lt;ulink linkType="Reference" linkID="1345696"&gt;1345696&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>· Center for Drug and Alcohol Programs,· Medical University of South Carolina</Name><Address1>Charleston,</Address1><Address2>South Carolina</Address2><Address3>29425</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Alcoholism</Disease><PatientSegments><PatientSegment><PatientSegment id="10890">Subjects with Craving for Alcohol</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00366626</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Alcoholism" id="22661"><Endpoint>Assessment of Alcohol Consumption</Endpoint><SubEndpoints><SubEndpoint disease="Alcoholism" id="22662">Quantity of alcohol consumed</SubEndpoint><SubEndpoint disease="Alcoholism" id="22663">Frequency of drinking</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Alcoholism" id="22688"><Endpoint>Assessment of Withdrawal Symptoms</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Alcoholism" id="22749"><Endpoint>Assessment of Brain Structure and Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Alcoholism" id="22764"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Alcoholism" id="22683"><Endpoint>Assessment of craving</Endpoint><SubEndpoints><SubEndpoint disease="Alcoholism" id="22685">Assessment by Obsessive Compulsive Drinking Scale (OCDS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Alcoholism" id="22770"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Alcoholism" id="46891"><Endpoint>Gene variants involved in outcome measures</Endpoint><SubEndpoints><SubEndpoint disease="Alcoholism" id="46903">OPRM1_HUMAN_Mutation</SubEndpoint><SubEndpoint disease="Alcoholism" id="48638">COMT_HUMAN_rs4680(A)</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Alcoholism" id="19914"><Criterion>Subjects with Alcohol Use Disorders</Criterion><SubCriteria><SubCriterion disease="Alcoholism" id="19916">Subjects with alcohol dependence</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Alcoholism" id="19917"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion><SubCriteria><SubCriterion disease="Alcoholism" id="19918">Diagnosed by Diagnostic and Statistical Manual (DSM IV) criteria</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Alcoholism" id="17579"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Alcoholism" id="17580">Subjects with other substance related disorders</SubCriterion><SubCriterion disease="Alcoholism" id="17581">Subjects co-morbid with developmental disorders</SubCriterion><SubCriterion disease="Alcoholism" id="17583">Subjects co-morbid with psychotic disorders</SubCriterion><SubCriterion disease="Alcoholism" id="17584">Subjects with eating disorders</SubCriterion><SubCriterion disease="Alcoholism" id="17585">Subjects with anxiety/mood disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alcoholism" id="17587"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Alcoholism" id="17595">Subjects co-morbid with metabolic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alcoholism" id="17589"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Alcoholism" id="17591"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Alcoholism" id="17592"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Alcoholism" id="17605"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Alcoholism" id="17606">Subjects with history /scheduled to receive GABA- agonist</SubCriterion><SubCriterion disease="Alcoholism" id="17607">Subjects with history /scheduled to receive non-selective opiate antagonist</SubCriterion><SubCriterion disease="Alcoholism" id="17612">Subjects with history /scheduled to receive psychotropic medication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alcoholism" id="17636"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Alcoholism" id="17638">Subjects with positive drug screen</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alcoholism" id="26039"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Alcoholism" id="17590">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Alcoholism" id="26301"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Alcoholism" id="17631">Subjects with abnormal/unacceptable liver function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-01-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2006-08-17T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-12-03T06:40:02Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="added"><Date>2019-04-18T00:00:00Z</Date><Reason id="313">Eligibility Criteria added</Reason></Change><Change type="added"><Date>2019-04-18T00:00:00Z</Date><Reason id="313">Eligibility Criteria added</Reason></Change></ChangeHistory></Trial><Trial id="100003"><TitleDisplay>99mTc-3PRGD2 SPECT/CT In Lung Cancer Patients</TitleDisplay><TitleOfficial>Safety And Diagnostic Performance Of 99mTc-3PRGD2 SPECT/CT In Evaluation Of Lung Cancer Patients</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">PUMCHNM05</Identifier><Identifier type="NCT">NCT01737112</Identifier><Identifier type="Trial Acronym">TcRGDLC</Identifier></Identifiers><Indications><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="2399">Adenocarcinoma</Indication><Indication id="307">Squamous cell carcinoma</Indication></Indications><BiomarkerNames><BiomarkerName id="7" role="Therapeutic effect marker" type="Genomic;Proteomic">Antigen KI-67</BiomarkerName><BiomarkerName id="855" role="Therapeutic effect marker" type="Genomic;Proteomic">Hematopoietic progenitor cell antigen CD34</BiomarkerName><BiomarkerName id="1378" role="Therapeutic effect marker" type="Cellular">Microvessel density</BiomarkerName><BiomarkerName id="6054" role="Therapeutic effect marker" type="Proteomic">Integrin alphaVbeta3</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>18F-FDG</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>99mTc-3PRGD2</Name><Drug id="78815">99mTc-3PRGD2</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>PET/CT</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Single photon emission computed tomography (SPECT)/computed tomography</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="78815">99mTc-3PRGD2</Drug><IndicationsPioneer><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="2399">Adenocarcinoma</Indication><Indication id="307">Squamous cell carcinoma</Indication></IndicationsPioneer><Companies><Company><Company id="1039932">Peking Union Medical College Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="78815" type="Drug"><TargetEntity id="790579" type="siDrug">[99mTc]3PRGD2</TargetEntity></SourceEntity><SourceEntity id="1039932" type="Company"><TargetEntity id="5041082090" type="organizationId">Peking Union Medical College Hospital</TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"></TargetEntity><TargetEntity id="D002289" type="MeSH"></TargetEntity><TargetEntity id="-1730468577" type="omicsDisease"></TargetEntity><TargetEntity id="612" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2399" type="ciIndication"><TargetEntity id="10001141" type="MEDDRA"></TargetEntity><TargetEntity id="D000230" type="MeSH"></TargetEntity><TargetEntity id="-1620546969" type="omicsDisease"></TargetEntity><TargetEntity id="656" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="307" type="ciIndication"><TargetEntity id="10041823" type="MEDDRA"></TargetEntity><TargetEntity id="D002294" type="MeSH"></TargetEntity><TargetEntity id="-1612557995" type="omicsDisease"></TargetEntity><TargetEntity id="676" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1039932">Peking Union Medical College Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="6063">Integrin alpha-V/beta-3 modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="4155">Imaging agent</Class><Class id="5556">SPECT contrast agent</Class><Class id="5720">Radiodiagnostic</Class><Class id="7220">Neoplasm diagnostic agent</Class></Class><Technologies><Technology id="731">Imaging</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="80">Peptide</Technology><Technology id="724">Radiolabeling</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Diagnostic</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Diagnosis</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><PatientCountEvaluable>91</PatientCountEvaluable><DateStart>2011-02-28T00:00:00Z</DateStart><DateEnd type="estimated">2017-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-16T16:16:26Z</DateChangeLast><DateAdded>2012-12-03T09:06:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science</Affiliation><Email>zhu_zhaohui@yahoo.cn</Email><Name>Zhaohui Zhu, MD</Name><Phone>86-10-69154196</Phone></Contact><Contact type="Scientific contact"><Affiliation>Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science</Affiliation><Email>lifang@pumch.cn</Email><Name>Fang Li, MD</Name><Phone>86-10-69155502</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Males and females,  &gt;/= 30 years old&lt;/li&gt;&lt;li&gt;Thoracic CT and/or 18F-FDG PET/CT diagnosis in suspicion of primary or recurrent lung
             cancer&lt;/li&gt;&lt;li&gt;The lung cancer will be histologically confirmed or results of histology will be
             available&lt;/li&gt;&lt;li&gt;Patients with pathological diagnosis (adenocarcinoma; squamous cell carcinoma)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Females planning to bear a child recently or with childbearing potential&lt;/li&gt;&lt;li&gt;Known severe allergy or hypersensitivity to IV radiographical contrast&lt;/li&gt;&lt;li&gt;Inability to lie still for the entire imaging time because of cough, pain, etc&lt;/li&gt;&lt;li&gt;Inability to complete the needed examinations due to severe claustrophobia, radiation
             phobia, etc&lt;/li&gt;&lt;li&gt;Concurrent severe and/or uncontrolled and/or unstable other medical disease that, in
             the opinion of the Investigator, may significantly interfere with study compliance&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Visual and semiquantitative assessment of lesions and biodistribution: visual analysis will be performed by consensus reading by at least three experienced nuclear medicine physician. The semiquantitative analysis will be performed by the same person for all the cases, and the tumor to background ratios(T/B) will be measured</Description><Timeframe>One year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Assessment of lymph-node involvement</Description></Measure><Measure><Description>Adverse events collection: adverse events within 5 days after the injection and scanning of the patients will be followed and assessed</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Response evaluation of chemotherapy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was an open-label SPECT/CT (single photon emission computed tomography / computed
      tomography) study to investigate the safety and diagnostic performance of &lt;ulink linkType="Drug" linkID="78815"&gt;99mTc-3PRGD2&lt;/ulink&gt; in
      evaluation of lung cancer patients.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In September 2013, results from patients with suspicious lung lesions or biopsy proven non-small cell lung cancer  were presented. The comparable diagnostic accuracy in differentiation of lung lesions was comparable between &lt;ulink linkType="Drug" linkID="78815"&gt;99mTc-3PRGD2&lt;/ulink&gt; SPECT/CT and 18F-FDG PET/CT (p = 0.410). The sensitivity, specificity, and accuracy were 87.5%, 98.2%, and 89.5%, respectively, for &lt;ulink linkType="Drug" linkID="78815"&gt;99mTc-3PRGD2&lt;/ulink&gt; SPECT/CT versus 82.2%, 66.1%, and 79.3%, respectively for 18F-FDG PET/CT, which shows the &lt;ulink linkType="Drug" linkID="78815"&gt;99mTc-3PRGD2&lt;/ulink&gt; SPECT/CT was significantly better in the assessment of lymph-node involvement (p &amp;lt; 0.0001). But, only less remote metastases was detected by whole-body &lt;ulink linkType="Drug" linkID="78815"&gt;99mTc-3PRGD2&lt;/ulink&gt; planar scan (76.4%) compared to 18F-FDG PET/CT. The two methods were identical in 76.2% patients in terms of response evaluation of chemotherapy, whereas in other patients, both the methods showed advantages and disadvantages. A positive correlation was observed between uptake of &lt;ulink linkType="Drug" linkID="78815"&gt;99mTc-3PRGD2&lt;/ulink&gt;  with integrin alphavbeta3 receptor expression (r = 0.837, p &amp;lt; 0.001) and the microvessel density (r = 0.633, p = 0.011) [&lt;ulink linkType="Reference" linkID="1475787"&gt;1475787&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, results were presented. After 1- and 3-cycle treatment, there was significant difference of tumor-to-background ratio of 99mTc-3PRGD2 uptake between the patients with the RECIST partial response (PR) and stable disease (SD) (-22.69 +/- 24.30, n = 7 versus -8.35 +/- 7.64, n = 22, respectively; p = 0.026) and (-41.76 +/- 26.62, n = 1 5 versus -17.57 +/- 19.81, n = 16; p = 0.007), respectively. By revealing the receptor change, the 99mTc-3PRGD2 SPECT/CT evaluation seemed to be more reliable rather than the metabolic change, with probably less influence caused by hypoxia and temporary metabolic inhibition, as well as the uptake variation in muscle, bone marrow, and myocardium when compared with the PERCIST [&lt;ulink linkType="Reference" linkID="1666577"&gt;1666577&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2015, results were published. 99mTc-3PRGD2 was rapidly cleared from the blood pool and primarily excreted through the urinary system. The standardized uptake values of proven malignancies were significantly higher than those of the benign ones. With an average standardized uptake value of &amp;gt; 1.3 being considered malignant, the sensitivity, specificity, and accuracy of 99mTc-3PRGD2 PET/CT in diagnosing lung cancer were 83.8, 91.3, and 85.7%, respectively. The diagnostic value of 99mTc-3PRGD2 for lungcancer was comparable to that of F-18-FDG PET/CT. But 99mTc-3PRGD2 PET/CT was more specific than F-18-FDG PET/CT in assessing lymph node metastasis, with positive and negative predictive values of 90.0 and 93.8%, respectively, whereas those of F-18-FDG PET/CT were 30.2 and 90.5%, respectively [&lt;ulink linkType="Reference" linkID="1724398"&gt;1724398&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2016, results were published. More specific in per-region diagnosis of lymph node metastasis, was found in 99mTc-3PRGD2 SPECT/CT, when compared to 18F- FDG PET/CT (specificity, 94.6 versus 75.0%; p = 0.008) when the sensitivity of the two methods was comparable (88.3 versus 90.7%; p = 0.557). In two methods, no differences in the per- lesion diagnosis of lung tumor (z = 0.82, p = 0.410), was observed. A positive correlation between the accumulation level of 99mTc- 3PRGD2 and integrin alphav beta3 expression (r = 0.84, p = 0.001) and microvessel density (r = 0.63, p = 0.011) in the tumors was observed [&lt;ulink linkType="Reference" linkID="1941219"&gt;1941219&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A single dose of nearly 11.1   MBq/kg body weight of
      &lt;ulink linkType="Drug" linkID="78815"&gt;99mTc-3PRGD2&lt;/ulink&gt; (&amp;lt;/= 20 microg 3PRGD2) would be intravenously injected into the patients in suspicion
      of lung cancer. Visual and semiquantitative method would be used to assess the whole-body
      planar and thoracic SPECT/CT images. Any adverse events would be collected from the patients.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received &lt;ulink linkType="Drug" linkID="78815"&gt;99mTc-3PRGD2&lt;/ulink&gt; (11.1 MBq/kg body weight), iv and underwent whole-body planar scanning and chest SPECT/CT successively 1 h after the injection [&lt;ulink linkType="Reference" linkID="1475787"&gt;1475787&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1666577"&gt;1666577&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1724398"&gt;1724398&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patients underwent both 99mTc- 3PRGD2 SPECT/CT and fluorine 18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT within 1 week [&lt;ulink linkType="Reference" linkID="1941219"&gt;1941219&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Department of Nuclear Medicine, Peking Union Medical College Hopital, Chinese Academy of Medical Science</Name><Address1>Beijing</Address1><Address3>100730</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>lifang@pumch.cn</Email><Name>Fang Li, MD</Name><Phone>86-10-69155502</Phone></Contact><Contact type="Facility contact backup"><Email>zhuzhh@pumch.cn</Email><Name>Zhaohui Zhu, MD</Name><Phone>86-10-69154196</Phone></Contact><Contact type="Facility investigator"><Name>Zhaohui Zhu, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lung tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3650">Subjects with Recurrent/Relapsed Lung Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01737112</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lung tumor" id="8563"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lung tumor" id="8639"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Lung tumor" id="8593"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8595">Evaluation by MRI/CT scan</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lung tumor" id="3910"><Criterion>Subjects with Primary Lung Cancer</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3913"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3956"><Criterion>Subjects Confirmed of Lung Cancer by Specific Modes</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3957">Subjects with cytologically/histologically confirmed diagnosis of lung cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="4000"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lung tumor" id="5344"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5365">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="20281"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Lung tumor" id="27883"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5349">Subjects unable/unwilling to comply with protocol requirements</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2017-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2012-11-27T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-12-03T09:06:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-01-23T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="100004"><TitleDisplay>S-ICD System Post Approval Study</TitleDisplay><TitleOfficial>S-ICD System Post Approval Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">BSC CRM CDM00055718</Identifier><Identifier type="NCT">NCT01736618</Identifier></Identifiers><Indications><Indication id="1557">Cardiac arrest</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>S-ICD System</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="27847" type="Company"><TargetEntity id="4295903586" type="organizationId">Boston Scientific Corp</TargetEntity></SourceEntity><SourceEntity id="1557" type="ciIndication"><TargetEntity id="I46" type="ICD10"></TargetEntity><TargetEntity id="427.5" type="ICD9"></TargetEntity><TargetEntity id="10007515" type="MEDDRA"></TargetEntity><TargetEntity id="D006323" type="MeSH"></TargetEntity><TargetEntity id="-502675543" type="omicsDisease"></TargetEntity><TargetEntity id="2007" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>87</NumberOfSites><CompaniesSponsor><Company id="27847">Boston Scientific Corp</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>1766</PatientCountEnrollment><DateStart>2013-03-12T00:00:00Z</DateStart><DateEnd type="estimated">2021-10-31T00:00:00Z</DateEnd><DateChangeLast>2018-03-15T02:12:27Z</DateChangeLast><DateAdded>2012-12-03T12:23:40Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Boston Scientific Corporation</Affiliation><Name>Maria Macuare-Gorden, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Eligible for implantation with an S-ICD system, or previously implanted with an S-ICD
             system in the S-ICD system clinical investigation (IDE G090013)&lt;/li&gt;&lt;li&gt;Willing and able to provide written informed consent or have informed consent
             provided by a legal representative&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Remaining life expectancy of&amp;lt; 360 days&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Type I complication free rate: type I complications are adverse events caused by a component of the S-ICD System (ie, pulse generator, electrode, EIT or programmer) that results in permanent loss of device function, invasive intervention or death</Description><Timeframe>60 months (1800 days)</Timeframe></Measure><Measure><Description>Overall shock effectiveness in converting spontaneous discrete episodes of VT/VF: overall shock effectiveness refers to conversion of an episode following on any of the five shocks (maximum) that may be delivered during a single episode. Discrete episodes of VT/VF are those that are temporally independent (&lt; 3 within a 24 h period), unlike storm episodes, which occur in clusters (&gt;/= 3 episodes within a 24 h period). Episodes that spontaneously terminate will be excluded from this endpoint since the effectiveness of the shock cannot be evaluated in such circumstances</Description><Timeframe>60 months (1800 days)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Electrode-related complication free rate: a complication is an adverse event that results in permanent loss of device function, invasive intervention or death</Description><Timeframe>60 months (1800 days)</Timeframe></Measure><Measure><Description>First shock effectiveness in converting induced (acute) and spontaneous discrete episodes of VT/VF</Description><Timeframe>60 months (1800 days)</Timeframe></Measure><Measure><Description>Freedom from complications requiring surgical revisions of the pulse generator or electrode, including pocket revisions, surgical repositioning or removal of the device in response to product performance issues</Description><Timeframe>60 months (1800 days)</Timeframe></Measure><Measure><Description>Individual rates of each adverse event category contributing to the primary and secondary safety endpoints: will be examined including two-sided 95% exact confidence intervals</Description><Timeframe>60 months (1800 days)</Timeframe></Measure><Measure><Description>All cause mortality</Description><Timeframe>60 months (1800 days)</Timeframe></Measure><Measure><Description>Electrical performance data recorded by the device</Description><Timeframe>60 months (1800 days)</Timeframe></Measure><Measure><Description>Mechanical electrode failures</Description><Timeframe>60 months (1800 days)</Timeframe></Measure><Measure><Description>Explants and causes</Description><Timeframe>60 months (1800 days)</Timeframe></Measure><Measure><Description>Transvenous ICD (TV-ICD) implantation following subcutaneous ICD (S-ICD) explant</Description><Timeframe>60 months (1800 days)</Timeframe></Measure><Measure><Description>Surgical revisions in response to suboptimal placement or system movement</Description><Timeframe>60 months (1800 days)</Timeframe></Measure><Measure><Description>Chronic pain/discomfort requiring surgical intervention</Description><Timeframe>60 months (1800 days)</Timeframe></Measure><Measure><Description>Removal of S-ICD System in response to implant testing</Description><Timeframe>60 months (1800 days)</Timeframe></Measure><Measure><Description>Syncope associated with VT/VF episodes</Description><Timeframe>60 months (1800 days)</Timeframe></Measure><Measure><Description>Inappropriate shock incidence</Description><Timeframe>60 months (1800 days)</Timeframe></Measure><Measure><Description>Premature battery depletions and other device malfunctions</Description><Timeframe>60 months (1800 days)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the S-ICD Post Approval Study is to document long-term safety and
      effectiveness outcomes associated with the implantation of the SQ-RX pulse generator and
      Q-TRAK electrode in a commercial clinical setting.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The S-ICD post approval study is a non-randomized registry that will retrospectively enroll
      subjects who participated in the S-ICD clinical investigation (IDE G090013) and
      prospectively enroll new candidates for the S-ICD System.  The target enrollment sample size
      is 1616 subjects at up to 150 investigational sites to achieve 1025 subjects in the
      analysis cohort at 60 months.&lt;/para&gt;&lt;para&gt;The primary safety endpoint of the study is the Type I (caused by the S-ICD System)
           complication free rate at 60 months compared to a performance goal of 85%&lt;br/&gt;The primary effectiveness endpoint is the overall shock effectiveness in converting
           spontaneous discrete episodes of VT/VF through 60 months compared to a performance goal
           of 94%&lt;br/&gt;The secondary safety endpoint of the study is the electrode-related complication free
           rate at 60 months compared to a performance goal of 92.5%&lt;br/&gt;The secondary effectiveness endpoint is first shock effectiveness in converting induced
           (acute) and spontaneous discrete episodes of VT/VF till 60 months compared to a
           performance goal of 84.0%&lt;br/&gt;Additional objectives include characterization of long term safety and effectiveness in
      subjects of varied body habitus and in traditionally underrepresented populations.&lt;br/&gt;Enrolled subjects will be followed at the implant procedure, predischarge and annual (+/- 60 days) follow-up visits. Subjects will be followed according to the standard of care at their participating investigational center.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Abbott Northwestern Hospital</Name><Address1>Minneapolis</Address1><Address2>Minnesota</Address2><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Advocate Health and Hospitals Corporation/Midwest Heart Foundation</Name><Address1>Lombard</Address1><Address2>Illinois</Address2><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Albany Medical Center</Name><Address1>Albany</Address1><Address2>New York</Address2><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Arizona Arrhythmia Consultants</Name><Address1>Phoenix</Address1><Address2>Arizona</Address2><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Arizona Arrhythmia Consultants, PLC</Name><Address1>Scottsdale</Address1><Address2>Arizona</Address2><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Barnes Jewish Hospital</Name><Address1>Saint Louis</Address1><Address2>Missouri</Address2><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Bergen Cardiology</Name><Address1>Omaha</Address1><Address2>Nebraska</Address2><CountrySubDivision code="NE">Nebraska</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Beth Israel Medical Center / Mount Sinai</Name><Address1>New York</Address1><Address2>New York</Address2><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Brigham and Women's Hosptial</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts></Contacts></Site><Site><Name>California Heart Associates</Name><Address1>Fountain Valley</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Cardiac Arrhythmia Services, Inc</Name><Address1>Fort Lauderdale</Address1><Address2>Florida</Address2><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Cardiovascular Associates of Mesa</Name><Address1>Mesa</Address1><Address2>Arizona</Address2><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Catholic Medical Center</Name><Address1>Manchester</Address1><Address2>New Hampshire</Address2><CountrySubDivision code="NH">New Hampshire</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Cooper University Hospital</Name><Address1>Camden</Address1><Address2>New Jersey</Address2><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Cox Health Center for Research and Innovation</Name><Address1>Springfield</Address1><Address2>Missouri</Address2><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Drexel Hahnemann University</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Duke University</Name><Address1>Durham</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Emory University</Name><Address1>Atlanta</Address1><Address2>Georgia</Address2><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Forsyth Medical Center</Name><Address1>Winston-Salem</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Georgia Health Sciences University</Name><Address1>Augusta</Address1><Address2>Georgia</Address2><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Good Samaritan Hospital</Name><Address1>Cincinnati</Address1><Address2>Ohio</Address2><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Gwinnett Medical Center</Name><Address1>Lawrenceville</Address1><Address2>Georgia</Address2><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>HeartPlace Mid-Cities EP</Name><Address1>Bedford</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Henry Ford Hospital</Name><Address1>Detroit</Address1><Address2>Michigan</Address2><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Hospital of the University of Pennsylvania</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Hunter Holmes VA Medical Center</Name><Address1>Richmond</Address1><Address2>Virginia</Address2><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Huntington Memorial Hospital/Foothill Cardiology</Name><Address1>Pasadena</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Huntsville Hospital</Name><Address1>Huntsville</Address1><Address2>Alabama</Address2><CountrySubDivision code="AL">Alabama</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Indiana University -Ball</Name><Address1>Muncie</Address1><Address2>Indiana</Address2><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Inova Fairfax</Name><Address1>Falls Church</Address1><Address2>Virginia</Address2><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>James A Haley Veterans Affairs Hospital</Name><Address1>Tampa</Address1><Address2>Florida</Address2><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Jersery Shore Medical Center</Name><Address1>Neptune</Address1><Address2>New Jersey</Address2><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts></Contacts></Site><Site><Name>John's Hopkins University</Name><Address1>Baltimore</Address1><Address2>Maryland</Address2><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Kootenai Heart Clinics</Name><Address1>Spokane</Address1><Address2>Washington</Address2><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Lake West Hospital</Name><Address1>Willoughby</Address1><Address2>Ohio</Address2><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Maimonides Hospital</Name><Address1>Brooklyn</Address1><Address2>New York</Address2><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Medical University of South Carolina</Name><Address1>Charleston</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Memorial Medical Center (UCH-MHS)</Name><Address1>Colorado Springs</Address1><Address2>Colorado</Address2><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Mercy Hospital</Name><Address1>Coon Rapids</Address1><Address2>Minnesota</Address2><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Mid-America Heart Institute - St. Luke's Hospital</Name><Address1>Kansas City</Address1><Address2>Missouri</Address2><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Mount Sinai</Name><Address1>New York</Address1><Address2>New York</Address2><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>North Texas Heart Center</Name><Address1>Dallas</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Northwestern University</Name><Address1>Chicago</Address1><Address2>Illinois</Address2><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Norton Audobon Hospital</Name><Address1>Louisville</Address1><Address2>Kentucky</Address2><CountrySubDivision code="KY">Kentucky</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novant Health Heart and Vascular</Name><Address1>Charlotte</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Ohio Health Research</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Oregon Health Sciences University</Name><Address1>Portland</Address1><Address2>Oregon</Address2><CountrySubDivision code="OR">Oregon</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Our Lady of Lourdes</Name><Address1>Sewell</Address1><Address2>New Jersey</Address2><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts></Contacts></Site><Site><Name>PIMA Heart Physicians, PC</Name><Address1>Tucson</Address1><Address2>Arizona</Address2><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Parkview Research Center</Name><Address1>Fort Wayne</Address1><Address2>Indiana</Address2><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Phoenix Cardiovascular Group</Name><Address1>Phoenix</Address1><Address2>Arizona</Address2><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Providence St. Joseph Medical Center</Name><Address1>Burbank</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Sentara Cardiovascular Research Institute</Name><Address1>Norfolk</Address1><Address2>Virginia</Address2><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Sequoia Hospital</Name><Address1>East Palo Alto</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Sharp Grossmont Hospital</Name><Address1>El Cajon</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Sharp Memorial Hospital</Name><Address1>San Diego</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>South Carolina Heart Center</Name><Address1>Columbia</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>St. John's Health Center</Name><Address1>Santa Monica</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>St. Joseph Hospital</Name><Address1>Savannah</Address1><Address2>Georgia</Address2><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>St. Luke's Unity Point</Name><Address1>Cedar Rapids</Address1><Address2>Iowa</Address2><CountrySubDivision code="IA">Iowa</CountrySubDivision><Contacts></Contacts></Site><Site><Name>St. Mary's Hospital</Name><Address1>Huntington</Address1><Address2>West Virginia</Address2><CountrySubDivision code="WV">West Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>St. Vincent's Ambulatory Care (Jacksonville, FL)</Name><Address1>Jacksonville</Address1><Address2>Florida</Address2><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>St. Vincent's Heart Clinic Arkansas</Name><Address1>Little Rock</Address1><Address2>Arkansas</Address2><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Stonybrook University Medical Center</Name><Address1>Stony Brook</Address1><Address2>New York</Address2><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Summa Health</Name><Address1>Akron</Address1><Address2>Ohio</Address2><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Temple University</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>The Cleveland Clinic</Name><Address1>Cleveland</Address1><Address2>Ohio</Address2><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>The Ohio State University</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>The Toledo Hospital</Name><Address1>Toledo</Address1><Address2>Ohio</Address2><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>The Vancouver Clinic</Name><Address1>Vancouver</Address1><Address2>Washington</Address2><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Union Memorial Hospital</Name><Address1>Baltimore</Address1><Address2>Maryland</Address2><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Univeristy of Texas Health Science Center</Name><Address1>Houston</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University Community Hospital (Florida Hospital)</Name><Address1>Tampa</Address1><Address2>Florida</Address2><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University Hospital (Augusta, GA)</Name><Address1>Augusta</Address1><Address2>Georgia</Address2><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University Hospital Cleveland</Name><Address1>Cleveland</Address1><Address2>Ohio</Address2><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of California- San Diego</Name><Address1>La Jolla</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Chicago</Name><Address1>Chicago</Address1><Address2>Illinois</Address2><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Michigan</Name><Address1>Ann Arbor</Address1><Address2>Michigan</Address2><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Southern California</Name><Address1>Los Angeles</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Utah Hospital and Clinic</Name><Address1>Salt Lake City</Address1><Address2>Utah</Address2><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Virginia Medical Center</Name><Address1>Charlottesville</Address1><Address2>Virginia</Address2><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Washington</Name><Address1>Seattle</Address1><Address2>Washington</Address2><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Valley Hospital</Name><Address1>New York</Address1><Address2>New York</Address2><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Vanderbilt University Medical Center</Name><Address1>Nashville</Address1><Address2>Tennessee</Address2><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Virginia Cardiovascular Specialists</Name><Address1>Richmond</Address1><Address2>Virginia</Address2><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Virginia Commonwealth Univeristy</Name><Address1>Richmond</Address1><Address2>Virginia</Address2><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Washington Hospital Center</Name><Address1>Washington</Address1><Address2>District of Columbia</Address2><CountrySubDivision code="DC">District of Columbia</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01736618</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><PrimaryCompletionDate type="Anticipated">2021-10-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2016-05-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>38.65 Months</EnrollmentPeriod><EnrollmentRate>45.69 Patients/Month</EnrollmentRate><DateFirstReceived>2012-11-27T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-12-03T12:23:40Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2016-12-07T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="100005"><TitleDisplay>Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis</TitleDisplay><TitleOfficial>A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study of Sevelamer Carbonate in CKD Patients on Hemodialysis</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">SVCARB03808</Identifier><Identifier type="NCT">NCT01736150</Identifier></Identifiers><Indications><Indication id="1003">Hyperphosphatemia</Indication></Indications><BiomarkerNames><BiomarkerName id="133" role="Therapeutic effect marker" type="Biochemical">Total cholesterol</BiomarkerName><BiomarkerName id="152" role="Therapeutic effect marker" type="Biochemical">Low-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="2382" role="Therapeutic effect marker" type="Biochemical">Phosphorus</BiomarkerName><BiomarkerName id="14767" role="Therapeutic effect marker" type="Biochemical">Lipids</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sevelamer carbonate (tablet, renal disease/hyperphosphatemia), Genzyme</Name><Drug id="49398">sevelamer carbonate (tablet, renal disease/hyperphosphatemia), Genzyme</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="49398">sevelamer carbonate (tablet, renal disease/hyperphosphatemia), Genzyme</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1009547">Sanofi SA</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="49398" type="Drug"><TargetEntity id="398609" type="siDrug">Sevelamer carbonate</TargetEntity></SourceEntity><SourceEntity id="1009547" type="Company"><TargetEntity id="4295868215" type="organizationId">Sanofi SA</TargetEntity></SourceEntity><SourceEntity id="1003" type="ciIndication"><TargetEntity id="10020711" type="MEDDRA"></TargetEntity><TargetEntity id="D054559" type="MeSH"></TargetEntity><TargetEntity id="-503652923" type="omicsDisease"></TargetEntity><TargetEntity id="1000" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>17</NumberOfSites><CompaniesSponsor><Company id="1009547">Sanofi SA</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="399">Hypoglycemic agent</Class><Class id="472">Phosphate lowering agent</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>205</PatientCountEnrollment><PatientCountEvaluable>205</PatientCountEvaluable><DateStart>2010-03-31T00:00:00Z</DateStart><DateEnd type="actual">2010-09-30T00:00:00Z</DateEnd><DateChangeLast>2018-12-13T10:09:41Z</DateChangeLast><DateAdded>2012-12-03T12:32:13Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Genzyme, a Sanofi Company</Affiliation><Name>Medical Monitor</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;On hemodialysis regimen scheduled for 4-h duration three times per week for a
             minimum 30 days prior to visit 1 and throughout the study&lt;/li&gt;&lt;li&gt;Have a central laboratory serum iPTH measurement&amp;lt; 1000 pg/ml at visit 1
&lt;/li&gt;&lt;li&gt;Have a central laboratory serum phosphorus measurement greater than 5.5 mg/dl at
             visit 1a&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Active dysphagia or swallowing disorder; or a predisposition to or current bowel
             obstruction, ileus, or severe gastrointestinal (GI) motility disorders including
             severe constipation&lt;/li&gt;&lt;li&gt;Documented poorly controlled diabetes mellitus, poorly controlled hypertension,
             active vasculitis, human immunodeficiency virus infection, or any clinically
             significant unstable medical condition&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change from baseline to visit 6/Early Termination (ET) in serum phosphorous</Description><Timeframe>8 weeks</Timeframe></Measure><Measure><Description>Frequency of treatment-emergent adverse events (AEs) and serious adverse events (SAEs), changes in laboratory parameters and changes in vital signs</Description><Timeframe>11 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change from baseline to visit 6/ET in serum lipids (total cholesterol and LDL-cholesterol)</Description><Timeframe>8 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Results published in October 2013, showed that    tolerability was observed to be  96 and 97%  in the sevelamer carbonate and placebo arms, respectively. Similar and consistent adverse events were observed among the two groups [&lt;ulink linkType="Reference" linkID="1492794"&gt;1492794&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study was to evaluate the efficacy and safety of &lt;ulink linkType="Drug" linkID="49398"&gt;sevelamer carbonate&lt;/ulink&gt; in reducing serum
      phosphorus and serum lipids (total and LDL-cholesterol) in chronic kidney disease patients
      on dialysis.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results published in October 2013, showed that there was a significant decrease in mean serum phosphorus and persistently elevated in patients receiving placebo (p &amp;lt; 0.0001).  Serum concentrations of  sevelamer carbonate reduced in as statistically significant manner, reduction in low-density lipoprotein (LDL) cholesterol was also observed (p &amp;lt; 0.0001 for both) [&lt;ulink linkType="Reference" linkID="1492794"&gt;1492794&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study would consist of the following arms:&lt;br/&gt;Arm I: the volunteers would be administered with a starting dose of one tablet of &lt;ulink linkType="Drug" linkID="49398"&gt;sevelamer carbonate&lt;/ulink&gt; (800 mg), tid (2.4 g/day) with meals. If serum phosphorus was &amp;gt; 5.5 mg/dl on visit 3, 4, or 5, then dose would be increased by one additional tablet (800 mg) .&lt;br/&gt;Arm II: the volunteers would be administered with a starting dose of one tablet (800 mg) of placebo, tid  (2.4 g/day) with meals. If serum phosphorus was &amp;gt; 5.5 mg/dl on visit 3, 4 or 5, then dose increased by one additional tablet (800 mg). &lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received sevelamer carbonate (starting dose 800 mg tid) or placebo over 8 weeks' duration [&lt;ulink linkType="Reference" linkID="1492794"&gt;1492794&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Peking Union Medical College Hospital</Name><Address1>Beijing</Address1><Contacts></Contacts></Site><Site><Name>Peking University First Hospital</Name><Address1>Beijing</Address1><Contacts></Contacts></Site><Site><Name>West China Hospital</Name><Address1>Chengdu</Address1><Contacts></Contacts></Site><Site><Name>Sichuan Provincial People's Hospital</Name><Address1>Chengdu</Address1><Contacts></Contacts></Site><Site><Name>Southwest Hospital</Name><Address1>Chongqing</Address1><Contacts></Contacts></Site><Site><Name>Guangzhou First Municipal People's Hospital</Name><Address1>Guangzhou</Address1><Contacts></Contacts></Site><Site><Name>Nanfang Hospital</Name><Address1>Guangzhou</Address1><Contacts></Contacts></Site><Site><Name>Sun Yat-Sen University School of Medicine 1st Affiliated Hospital</Name><Address1>Guangzhou</Address1><Contacts></Contacts></Site><Site><Name>Zhejiang University School of Medicine 1st Affiliated Hospital</Name><Address1>Hangzhou</Address1><Contacts></Contacts></Site><Site><Name>Zhongda Hospital of Southeast University</Name><Address1>Nanjing</Address1><Contacts></Contacts></Site><Site><Name>Jiangsu Province Hospital</Name><Address1>Nanjing</Address1><Contacts></Contacts></Site><Site><Name>Qingdao Municipal Hospital</Name><Address1>Qingdao</Address1><Contacts></Contacts></Site><Site><Name>Renji Hospital</Name><Address1>Shanghai</Address1><Contacts></Contacts></Site><Site><Name>Changzheng Hospital</Name><Address1>Shanghai</Address1><Contacts></Contacts></Site><Site><Name>Zhongshan Hospital</Name><Address1>Shanghai</Address1><Contacts></Contacts></Site><Site><Name>Xinhua Hospital</Name><Address1>Shanghai</Address1><Contacts></Contacts></Site><Site><Name>Shanghai Ruijin Hospital</Name><Address1>Shanghai</Address1><Contacts></Contacts></Site><Site><Name>Wenzhou College of Medicine 1st Affiliated Hospital</Name><Address1>Wenzhou</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>End stage renal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="7717">Subjects with Electrolyte Imbalance/Associated Complications</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="18963">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="7718">Subjects co-morbid with secondary hyperparathyroidism</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="20180">Subjects by disease severity</PatientSegment><SubSegments><SubSegment id="7702">Subjects with stage 5 chronic kidney disease/end stage renal disease(ESRD)</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01736150</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="End stage renal disease" id="22549"><Endpoint>Assessment of Serum Electrolytes</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22552">Assessment of phosphate</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22594"><Endpoint>Assessment of Vital Signs</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22595"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="End stage renal disease" id="22543"><Endpoint>Assessment of lipid profiles</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="End stage renal disease" id="17648"><Criterion>Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17652">Subjects with stage 5 CKD/end stage renal disease(ESRD)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="End stage renal disease" id="17678"><Criterion>Subjects with Electrolyte Imbalance/Associated Complications</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17679">Subjects with secondary hyperparathyroidism associated electrolyte imbalance</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="End stage renal disease" id="17519"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17524"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17525">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17531"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17552"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-09-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2012-11-26T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-12-03T12:32:13Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-01-06T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="100006"><TitleDisplay>A Study to Evaluate the Effect of ATG-F on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical SCT</TitleDisplay><TitleOfficial>An Investigator Initiated, Prospective, Randomized, Controlled Study in Order to Evaluate the Effect of Anti-thymocyte Globulin (Fresenius ATG) on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical Allogeneic Hematopoietic Stem-cell Transplantation</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">MYS-06-HMO-CTIL</Identifier><Identifier type="NCT">NCT00616954</Identifier></Identifiers><Indications><Indication id="199">Leukemia</Indication><Indication id="616">Graft versus host disease</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ATG-F</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="16594" type="Company"><TargetEntity id="5035523660" type="organizationId">Hadassah Medical Organization CC</TargetEntity></SourceEntity><SourceEntity id="199" type="ciIndication"><TargetEntity id="10024288" type="MEDDRA"></TargetEntity><TargetEntity id="D007938" type="MeSH"></TargetEntity><TargetEntity id="-609576380" type="omicsDisease"></TargetEntity><TargetEntity id="683" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="616" type="ciIndication"><TargetEntity id="D89.81" type="ICD10"></TargetEntity><TargetEntity id="10018651" type="MEDDRA"></TargetEntity><TargetEntity id="D006086" type="MeSH"></TargetEntity><TargetEntity id="39812" type="ORPHANET"></TargetEntity><TargetEntity id="-1437372564" type="omicsDisease"></TargetEntity><TargetEntity id="1129" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="16594">Hadassah Medical Organization</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>50</PatientCountEnrollment><DateStart>2008-05-31T00:00:00Z</DateStart><DateEnd type="actual">2010-09-30T00:00:00Z</DateEnd><DateChangeLast>2019-01-26T04:06:39Z</DateChangeLast><DateAdded>2012-12-03T12:01:22Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Hadassah Medical Organization</Affiliation><Name>Michael Y Shapira, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patient age 3 to 70 years old with a disease necessitating allogeneic SCT&lt;/li&gt;&lt;li&gt;Patients must have a mismatched donor willing and capable of donating peripheral
             blood stem cells and/or bone marrow progenitor cells using conventional techniques,
             and lymphocytes if indicated (mismatched defined as 3/6-4/6 HLA matching)&lt;/li&gt;&lt;li&gt;Each patient/patients guardian must sign written informed consent&lt;/li&gt;&lt;li&gt;Patients must have an ECOG PS&amp;lt;/= 2; creatinine &amp;lt; 2.0 mg/dl; ejection fraction &amp;gt; 40%;
             DLCO &amp;gt; 50% of predicted; serum bilirubin &amp;lt; 3 g/dl; elevated GPT or GOT &amp;gt; 3 x normal
             values&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Not fulfilling any of the inclusion criteria&lt;/li&gt;&lt;li&gt;Active life-threatening infection&lt;/li&gt;&lt;li&gt;Overt untreated infection&lt;/li&gt;&lt;li&gt;Known hypersensitivity to ATG&lt;/li&gt;&lt;li&gt;HIV seropositivity, hepatitis B or C antigen positivity with evidence of active
             hepatitis&lt;/li&gt;&lt;li&gt;Pregnant or lactating women&lt;/li&gt;&lt;li&gt;Donor contraindication (HIV seropositive confirmed by western blot hepatitis B
             antigenemia; positive HCV antibodies with positive HCV PCR; evidence of bone marrow
             disease; unable to donate bone marrow or peripheral blood due to concurrent medical
             condition)&lt;/li&gt;&lt;li&gt;Inability to comply with study requirements&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Day of day of neutrophil engraftment (ANC &gt; 0.5 x 10[9]/l)</Description><Timeframe>30 days</Timeframe></Measure><Measure><Description>Day of platelet engraftment &gt; 25 x 10(9)/l</Description><Timeframe>30 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>AGVHD occurrence</Description><Timeframe>100 days</Timeframe></Measure><Measure><Description>DFS (disease free survival)</Description><Timeframe>100 days</Timeframe></Measure><Measure><Description>Day of platelet engraftment &gt; 50 x 10(9)/l</Description><Timeframe>100 days</Timeframe></Measure><Measure><Description>Time to AGVHD</Description><Timeframe>100 days</Timeframe></Measure><Measure><Description>AGVHD grade</Description><Timeframe>100 days</Timeframe></Measure><Measure><Description>Overall survival</Description><Timeframe>100 days</Timeframe></Measure><Measure><Description>Infections incidence</Description><Timeframe>100 days</Timeframe></Measure><Measure><Description>Treatment-related mortality (TRM)</Description><Timeframe>100 days</Timeframe></Measure><Measure><Description>TRT</Description><Timeframe>100 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study was planned to evaluate whether &lt;ulink linkType="Drug" linkID="9298"/&gt;ATG (anti-thymocyte globulin) is needed in haploidentical stem cell
      transplantation.&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive either  ATG-F or control.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;This study was terminated due to low recruitment.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Israel"><Sites><Site><Name>Hadassah Medical Organization</Name><Address1>Jerusalem</Address1><Address3>91120</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Stem cell transplantation</Disease><PatientSegments><PatientSegment><PatientSegment id="10713">Subjects with History of/Indicated for Allogenic Stem Cell Transplantation(SCT)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10714">Subjects with History of/Indicated for Hematopoietic Stem Cell Transplantation(HSCT)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10724">Subjects with/ at Risk of Complications of Stem Cell Transplantation</PatientSegment><SubSegments><SubSegment id="10725">Subjects with/at risk of GVHD</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="11503">Subjects with History of/Indicated for Peripheral Blood Stem Cell Transplantation(PBSC)</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Leukemia</Disease><PatientSegments><PatientSegment><PatientSegment id="3986">Pediatric Leukemia Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Graft versus host disease</Disease><PatientSegments><PatientSegment><PatientSegment id="11337">Subjects with/at Risk of Acute Graft-versus-Host disease (GVHD)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11338">Subjects with/at Risk of Chronic Graft-versus-Host disease (GVHD)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11347">Subjects with History of/Scheduled for Graft-versus-Host disease (GVHD) Prophylaxis</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00616954</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Leukemia" id="9298"><Endpoint>Assessment of Engraftment</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8132">Assessment of time to engraftment</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Stem cell transplantation" id="17487"><Endpoint>Assessment of Engraftment</Endpoint><SubEndpoints><SubEndpoint disease="Stem cell transplantation" id="17490">Assessment of neutrophil/PMN recovery/engraftment</SubEndpoint><SubEndpoint disease="Stem cell transplantation" id="17491">Assessment of platelet recovery/engraftment</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Graft versus host disease" id="20155"><Endpoint>Assessment of Engraftment</Endpoint><SubEndpoints><SubEndpoint disease="Graft versus host disease" id="20157">Assessment of time to engraftment</SubEndpoint><SubEndpoint disease="Graft versus host disease" id="20159">Assessment of hematopoetic/immune reconstitution</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Leukemia" id="7879"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7885"><Endpoint>Assessment of Disease Free Survival (DFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8077"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8088">Assessment of risk or incidence of infections</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8109"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8117">Assessment of treatment-related mortality (TRM)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8126"><Endpoint>Assessment of Graft-Versus-Host Disease (GVHD)</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8127">Incidence of acute graft-vs-host disease</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="9298"><Endpoint>Assessment of Engraftment</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8132">Assessment of time to engraftment</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stem cell transplantation" id="17396"><Endpoint>Assessment of Graft-Versus-Host Disease (GVHD)</Endpoint><SubEndpoints><SubEndpoint disease="Stem cell transplantation" id="17400">Assessment of grade and severity of graft-vs-host disease</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stem cell transplantation" id="17405"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stem cell transplantation" id="17407"><Endpoint>Assessment of Disease Free Survival (DFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stem cell transplantation" id="17460"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Stem cell transplantation" id="17463">Assessment of infections</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stem cell transplantation" id="17468"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Stem cell transplantation" id="17471">Assessment of treatment-related mortality/non-relapse mortality</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stem cell transplantation" id="17487"><Endpoint>Assessment of Engraftment</Endpoint><SubEndpoints><SubEndpoint disease="Stem cell transplantation" id="17491">Assessment of platelet recovery/engraftment</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Graft versus host disease" id="20137"><Endpoint>Assessment of Acute Graft Versus Host Disease (aGVHD)</Endpoint><SubEndpoints><SubEndpoint disease="Graft versus host disease" id="20138">Assessment by grade/severity of acute GVHD</SubEndpoint><SubEndpoint disease="Graft versus host disease" id="20139">Assessment of incidence/rate of acute GVHD</SubEndpoint><SubEndpoint disease="Graft versus host disease" id="20140">Assessment of time to/duration of acute GVHD</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Graft versus host disease" id="20155"><Endpoint>Assessment of Engraftment</Endpoint><SubEndpoints><SubEndpoint disease="Graft versus host disease" id="20157">Assessment of time to engraftment</SubEndpoint><SubEndpoint disease="Graft versus host disease" id="20159">Assessment of hematopoetic/immune reconstitution</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Graft versus host disease" id="20162"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Graft versus host disease" id="20163"><Endpoint>Assessment of Disease Free Survival (DFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Graft versus host disease" id="20203"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Graft versus host disease" id="20206">Assessment of infections &amp; its complications</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Graft versus host disease" id="20208"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Graft versus host disease" id="20209">Assessment of non-relapse mortality/treatment related mortality</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Leukemia" id="5071"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5073">Subjects with normal/adequate liver function</SubCriterion><SubCriterion disease="Leukemia" id="5075">Subjects with normal/acceptable cardiac function</SubCriterion><SubCriterion disease="Leukemia" id="5076">Subjects with normal/acceptable pulmonary function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5085"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5086">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Leukemia" id="5087">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Leukemia" id="5088">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="7092"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5120">Subjects with history of anti-cancer biological therapy</SubCriterion><SubCriterion disease="Leukemia" id="5139">Subjects with history of stem cell therapy for leukemia</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stem cell transplantation" id="17842"><Criterion>Subjects with History of/Indicated for Allogeneic Stem Cell Transplantation(SCT)</Criterion><SubCriteria><SubCriterion disease="Stem cell transplantation" id="18297">Subjects with history of/indicated for SCT from living donor</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stem cell transplantation" id="17850"><Criterion>Subjects with History of/Indicated for Hematopoietic Stem Cell Transplantation(HSCT)</Criterion></Inclusion><Inclusion disease="Stem cell transplantation" id="17853"><Criterion>Subjects with History of/Indicated for Peripheral Blood Stem Cell Transplant(PBSC)</Criterion></Inclusion><Inclusion disease="Graft versus host disease" id="18757"><Criterion>Subjects with Protocol Specified Performance Status </Criterion></Inclusion><Inclusion disease="Graft versus host disease" id="18758"><Criterion>Subjects Included Based on HLA Matching/Relation to the Donor</Criterion><SubCriteria><SubCriterion disease="Graft versus host disease" id="18760">Subjects with related partially matched/mismatched HLA donor</SubCriterion><SubCriterion disease="Graft versus host disease" id="18762">Subjects with unrelated partially matched/mismatched donor</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Graft versus host disease" id="18766"><Criterion>Subjects with History of/Indicated for Transplant Procedure</Criterion><SubCriteria><SubCriterion disease="Graft versus host disease" id="18767">Subjects with history of/indicated for allogenic transplants</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Graft versus host disease" id="18783"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion><SubCriteria><SubCriterion disease="Graft versus host disease" id="18787">Subjects with required/adequate liver function status</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Graft versus host disease" id="33584"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Graft versus host disease" id="18789">Subjects with normal/acceptable cardiac function</SubCriterion><SubCriterion disease="Graft versus host disease" id="18790">Subjects with normal/acceptable pulmonary function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34013"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5074">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Graft versus host disease" id="34047"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Graft versus host disease" id="18788">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Leukemia" id="6554"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Leukemia" id="6596"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6617">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stem cell transplantation" id="15718"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Stem cell transplantation" id="15723">Subjects with history of infections</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stem cell transplantation" id="15839"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Stem cell transplantation" id="15849">Subjects with contraindication to procedures</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Graft versus host disease" id="16747"><Criterion>Subjects with/Predisposed to Local/Systemic Infections</Criterion></Exclusion><Exclusion disease="Graft versus host disease" id="16776"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Graft versus host disease" id="26489"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Graft versus host disease" id="16748">Subjects co-morbid with HIV infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Graft versus host disease" id="26771"><Criterion>Subjects co-morbid with Hepatic Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Graft versus host disease" id="16749">Subjects co-morbid with hepatitis</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-06-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2008-01-22T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-12-03T12:01:22Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput>